INFLUENZA-SHINGRIX
Posted on 29 December 2025
This cohort consist of 147 young (18-35 years of age) and older (≥60) individuals who received an inactivated quadrivalent seasonal influenza vaccine (Fluarix Tetra, IIV4), an adjuvanted herpes zoster vaccine (Shingrix, RZV) or a placebo.
The volunteer recruitment in this single-center, randomized, partially placebo-controlled, open-label
study was conducted at and sponsored by the Radboud University Medical Center between September 2021 and May 2023. After signing the informed consent form, young participants were randomized to receive either IIV4, RZV, IIV4-associated placebo or RZV-associated placebo (3:3:1:1), and older participants were randomized to receive either IIV4 or RZV (1:1).
The RZV and associated placebo groups received a second dose two months after the first injection. Study participants were followed for 6 months after the first visit in the IIV4 and associated placebo group and 8 months after the first visit in the RZV and associated placebo group (6 months after the second injection).
In this cohort, the available data are as follows:
- – Demographics and health-related information
- – Cytokine production upon incubation with various stimuli
- – Immunophenotyping
- – Serology
- – Antigen-specific T cell responses
- – Proteomics
- – Metabolomics
- – Transcriptomics
- – Epigenetics
The Influenza-Shingrix study was approved by the Medical Research Ethics Committee (MREC) Oost-Nederland (NL76061.091.20) and published at ClinicalTrials.gov (NCT05082688).
Selected Publications
Kilic, G., Taks, E. J., Helder, L. S., Dulfer, E. A., Geckin, B., van Emst, L., Lemmers, H., Berrè, S., Biswas, A., Ozturk, M., Negishi, Y., Burny, W., Buonocore, S. M., Ten Oever, J., Mhlanga, M. M., & Netea, M. G. (2026). Age-related differences in immune responses to inactivated influenza and adjuvanted recombinant herpes zoster vaccines. JCI insight, e195618. Advance online publication. https://doi.org/10.1172/jci.insight.195618